Country: United States
Language: English
Source: NLM (National Library of Medicine)
MUPIROCIN (UNII: D0GX863OA5) (MUPIROCIN - UNII:D0GX863OA5)
Medimetriks Pharmaceuticals Inc
MUPIROCIN
MUPIROCIN 20 mg in 1 g
TOPICAL
PRESCRIPTION DRUG
CENTANY® ointment is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes . CENTANY® ointment is contraindicated in patients with a history of sensitivity reactions to any of its components. Pregnancy Category B There are no adequate and well-controlled studies of CENTANY® ointment in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Developmental toxicity studies have been performed with mupirocin administered subcutaneously to rats and rabbits at doses up to 22 and 43 times, respectively, the human topical dose (approximately 60 mg mupirocin per day) based on body surface area. There was no evidence of fetal harm due to mupirocin. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CENTANY® ointment is administered to a nursing woman. The safety and effectiveness o
CENTANY® ointment, 2% is a white soft ointment and is supplied as follows: 30 g tube (NDC 43538-300 -30) Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].
New Drug Application
CENTANY- MUPIROCIN OINTMENT MEDIMETRIKS PHARMACEUTICALS INC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE CENTANY OINTMENT SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CENTANY OINTMENT. CENTANY (MUPIROCIN) OINTMENT, FOR TOPICAL USE INITIAL U.S. APPROVAL: 2002 INDICATIONS AND USAGE CENTANY ointment is an antibacterial drug indicated for the topical treatment of impetigo due to: _Staphylococcus_ _aureus _and _Streptococcus pyogenes._ (1) DOSAGE AND ADMINISTRATION A small amount of CENTANY ointment should be applied to the affected area three times daily or as directed by a physician. (2) The area treated may be covered with a gauze dressing if desired. (2) Patients not showing a clinical response within 3 to 5 days should be re-evaluated. (2) DOSAGE FORMS AND STRENGTHS Ointment: 2% (3) CONTRAINDICATIONS CENTANY ointment is contraindicated in patients with a history of sensitivity reactions to any of its components. (4) WARNINGS AND PRECAUTIONS Severe Allergic Reactions: Including anaphylaxis, urticaria, angioedema, and generalized rash have been reported in patients treated with CENTANY ointment. (5.1) Eye and Nose Irritation: Not intended for ophthalmic use or nasal use or on mucosal surfaces. (5.2) Local Irritation: If signs of sensitivity or irritation should occur, treatment should be discontinued. (5.3) _Clostridium difficile_-associated Diarrhea (CDAD): If diarrhea occurs, evaluate patients for CDAD. (5.4) Potential for Microbial Overgrowth: Prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (5.5) ADVERSE REACTIONS Most common adverse reactions (≥0.3%) are application site reactions, pruritus, contact dermatitis, furunculosis, exfoliative dermatitis and rash. (6.1) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT PERRIGO AT 1-866-634-9120 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS The effect of concurrent application of CENTANY ointment and other drug products is Read the complete document